Clinical due diligence (DD) for investment into a rare disease therapy: A pharma company was evaluating a small molecule therapy for potential investment. The therapy was in Phase III trials for a pediatric neurodegenerative rare disease and the company wanted to take expert opinion from a KOL as one data point in their technical DD.

Atlantis AI360 search engine jumped into action and in a matter of minutes, generated content documenting the latest scientific literature, disease pathology, clinical evidence, competitors, available treatment alternatives as well as geolocation mapping of labs and sites involved in scientific and clinical research in the disease area.

Atlantis AI360 identified several research clusters – for example, one at University of Pennsylvania, one at Universidad Autónoma de Madrid in Spain and one at Monash University in Australia.

Several KOLs were contacted and within a span of 12 hours, a Professor and Head of Regenerative Neuroscience and Development responded, and a call was scheduled in 48 hours, thereby completing a key aspect of scientific DD.